Skip to content
DataLookout
Menu

NCT06420830

Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 1, 2026 to Oct 1, 2027
    • Eligibility criteria shortened, about 2 words
    • Publications: details revised at 7 of 7 entries
  2. Notable Primary completion date: Sep 1, 2025 to Oct 1, 2026
    • Site contact updated
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 1, 2024 to Sep 1, 2025
    • Start date changed from estimate of Jun 1, 2024 to May 16, 2024
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Transvalvular gradient
Timeframe: 1-3 months
Effective orifice area (EOA)
Timeframe: 1-3 months
Prosthesis-patient mismatch
Timeframe: 1-3 months
Paravalvular leaks
Timeframe: 1-3 months

Secondary (8)

Transvalvular gradient
Effective orifice area (EOA)
Bioprosthetic valve dysfunction
Paravalvular leaks
Bioprosthetic valve failure
Show 3 moreShow less
Clinical events
Valve thrombosis
Valve endocarditis

Arms and interventions

Procedures: SAPIEN 3 Ultra RESILIA Valve

Sites

1 site in 1 country

  • IUCPQQuébec, Quebec, Canada